Incyte (INCY)
Developer of Jakafi, Opzelura, and targeted hematology, oncology, and immune-disease medicines.
Something off on this page? Send us feedback.
Discovers and sells medicines for hematology, oncology, and inflammatory and autoimmune diseases, led by Jakafi and Opzelura, while earning royalties from partner-marketed drugs. Operates as one segment, with Jakafi the largest sales contributor and the portfolio expanding through internal research, licensing, and acquisitions.
Discovers, develops, and commercializes proprietary medicines across hematology, oncology, and inflammation and autoimmunity. Jakafi and Jakafi XR treat myelofibrosis, polycythemia vera, and graft-versus-host disease, while Opzelura addresses atopic dermatitis and vitiligo. Niktimvo, Monjuvi/Minjuvi, Iclusig, Pemazyre, and Zynyz broaden the marketed portfolio across blood cancers, transplant complications, and solid tumors.
Runs clinical development and commercial operations from the United States, Europe, Japan, and Canada, and earns royalties from partner-marketed Jakavi, Olumiant, and Tabrecta. Builds franchises through internal discovery, licensing, and acquisitions; the completed Vega transaction added late-stage bleeding-disorder candidate latarcibart.
Operates as one reportable segment. Jakafi remains the largest sales contributor, while approvals, reimbursement, patent protection, collaboration agreements, and third-party manufacturing govern access and supply.
Company facts
Target rangeAs of Sep 21, 2026
Latest analyst notes
| Date | Firm | Action | Prior | Current |
|---|---|---|---|---|
| Aug 20, 2026 | Canaccord Genuity | Target | Target: — | Target: $152 |
| Aug 17, 2026 | Piper Sandler | Reiterate | Rating: —Target: $110 | Target: $130 |
| Aug 13, 2026 | Bernstein | Reiterate | Rating: —Target: $99 | Target: $104 |
| Aug 3, 2026 | Leerink Partners | Reiterate | Rating: —Target: $63 | Target: $155 |
| Jul 29, 2026 | RBC Capital | Reiterate | Rating: —Target: $99 | Target: $109 |
EPSReportedEstimate
RevenueReportedEstimate
Balance sheet, Jun 30, 2026Cash & short-term investments $4.54B · Total debt $38.3M · Total assets $7.87B · Shareholders' equity $6.34B
- Revenue
- $1.67B
- Operating income
- $697.9M
- Net income
- $585.6M
No dividends on record.
| Institutions | ≈ 98.66% | 199.99M shares | |
|---|---|---|---|
| 879 holders · as of Jun 30, 2026 · largest filers plus last quarter's tail | |||
| Insiders | 0.74% | 1.50M shares | |
| 26 holders · as of Sep 17, 2026 | |||
| Other | ≈ 0.60% | 1.21M shares | |
| remainder | |||
202.70M company shares as of Sep 22, 2026 · institutions as of Jun 30, 2026 · holders as of their latest filing
This quarter's institutional total failed a plausibility check; shown: the largest filers plus last quarter's remainder.
Top shareholders13F · 13D/G · Form 4
| Holder | Stake | Shares | Date |
|---|---|---|---|
Baker Bros. Advisors LPInstitution | 15.18% | 30.76M | as of Jun 30, 2026 |
BlackRock, Inc.Institution | 8.90% | 18.03M | as of Jun 30, 2026 |
Dodge & CoxInstitution | 5.90% | 11.96M | as of Jun 30, 2026 |
Vanguard Specialized Funds Vanguard Health Care FundInstitution | 5.48% | 11.11M | filed Jan 31, 2019 |
Vanguard Capital Management LLCInstitution | 5.44% | 11.02M | as of Jun 30, 2026 |
Insider tradesForm 4
| Date | Insider | Role | Shares | Avg price |
|---|---|---|---|---|
| Sep 15, 2026 | Pablo J. Cagnoni | officer: President, Global Head of R&D | −23,218 | $120.49 |
| Aug 19, 2026 | Pablo J. Cagnoni | officer: President, Global Head of R&D | −10,801 | $125.56 |
| Aug 12, 2026 | Pablo J. Cagnoni | officer: President, Global Head of R&D | −10,803 | $120.04 |
| Aug 5, 2026 | Patrick A. Mayes | officer: EVP & Chief Scientific Officer | −2,207 | $123.99 |
| Aug 5, 2026 | Pablo J. Cagnoni | officer: President, Global Head of R&D | −10,640 | $122.69 |
- GSK (ADR)
Ojjaara challenges Jakafi in anemia-linked myelofibrosis
- Bristol-Myers Squibb
Inrebic contests Jakafi in myelofibrosis treatment
- AbbVie
Rinvoq pressures Opzelura across JAK dermatology
- Sanofi (ADR)
Dupixent and Rezurock overlap Opzelura and GVHD care
- Pfizer
Cibinqo overlaps Opzelura in systemic AD care
- Organon
Vtama competes with Opzelura as a topical AD cream
- Arcutis Biotherapeutics
Zoryve contests Opzelura in topical eczema treatment
Compare
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| Incyte | $124.25 | −0.32% | $25.27B | 15.9 | 51.5 | 4.3 | +37.7% |
| GSK (ADR) | $50.29 | −1.55% | $102.34B | 16.1 | 9.2 | 2.3 | +5.3% |
| Bristol-Myers Squibb | $62.15 | −0.75% | $127.91B | 13.8 | 9.7 | 2.6 | +5.7% |
| AbbVie | $262.58 | −0.72% | $467.37B | 74.5 | 17.3 | 7.3 | +10.2% |
| Sanofi (ADR) | $42.07 | −1.01% | $102.05B | 75.6 | — | 1.8 | +11.2% |
| Pfizer | $27.57 | −0.63% | $158.10B | 36.7 | 9.8 | 2.5 | +2.6% |
| Organon | $13.68 | 0.00% | $3.59B | 17.8 | 3.9 | 0.6 | +0.5% |
| Arcutis Biotherapeutics | $26.40 | +1.69% | $3.25B | 124.5 | 33.5 | 7.0 | +59.3% |
| Median | 36.7 | 9.8 | 2.5 | +5.7% |